EyePoint Pharmaceuticals (STU:PV3B) COGS-to-Revenue

: 0.07 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

EyePoint Pharmaceuticals's Cost of Goods Sold for the three months ended in Dec. 2023 was €0.92 Mil. Its Revenue for the three months ended in Dec. 2023 was €12.86 Mil.

EyePoint Pharmaceuticals's COGS to Revenue for the three months ended in Dec. 2023 was 0.07.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. EyePoint Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 was 92.89%.

EyePoint Pharmaceuticals COGS-to-Revenue Historical Data

The historical data trend for EyePoint Pharmaceuticals's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Dec19

Dec20

Dec21

Dec22

Dec23

COGS-to-Revenue

0.13

0.17

0.22

0.20

0.10

EyePoint Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
COGS-to-Revenue																0.32	0.08	0.20	0.08	0.07

EyePoint Pharmaceuticals COGS-to-Revenue Calculation

EyePoint Pharmaceuticals's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	4.248	/	42.199
	=	0.10

EyePoint Pharmaceuticals's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.915	/	12.864
	=	0.07

EyePoint Pharmaceuticals (STU:PV3B) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

EyePoint Pharmaceuticals's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.915 / 12.864
	=	92.89 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

EyePoint Pharmaceuticals COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

EyePoint Pharmaceuticals (STU:PV3B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

EYPT:USA

Address

480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472

Website

https://www.eyepointpharma.com

EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines